Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Novavax, Inc.    NVAX

NOVAVAX, INC. (NVAX)
My previous session
Most popular
  Report  
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
10/11/2018 10/12/2018 10/15/2018 10/16/2018 10/17/2018 Date
1.91(c) 1.97(c) 1.95(c) 2.03(c) 2.03 Last
5 856 099 4 177 586 4 832 125 5 959 686 3 162 320 Volume
-0.52% +3.14% -1.02% +4.10% 0.00% Change
More quotes
Financials (USD)
Sales 2018 37,2 M
EBIT 2018 -180 M
Net income 2018 -190 M
Debt 2018 224 M
Yield 2018 -
Sales 2019 7,95 M
EBIT 2019 -197 M
Net income 2019 -208 M
Debt 2019 15,9 M
Yield 2019 -
P/E ratio 2018 -
P/E ratio 2019
EV / Sales2018 26,3x
EV / Sales2019 96,8x
Capitalization 754 M
More Financials
Company
Novavax, Inc. operates as a clinical-stage biopharmaceutical company, which engages in the provision of development of recombinant nanoparticle vaccines and adjuvants.Its product pipeline targets infectious diseases with vaccine candidates in clinical development for respiratory syncytial virus,... 
Sector
Biotechnology & Medical Research
Calendar
11/01 | 04:30pmPresentation
More about the company
Surperformance© ratings of Novavax, Inc.
Trading Rating : Investor Rating :
More Ratings
Latest news on NOVAVAX, INC.
10/02NOVAVAX : to Highlight RSV Program Data at Two Upcoming Meetings
AQ
09/28NOVAVAX : Nanoparticle Flu Vaccine for Older Adults Begins Phase 2 Trial
AQ
09/26NOVAVAX : to Present at Two Upcoming Investor Conferences
AQ
09/25NOVAVAX : Initiates Phase 2 Clinical Trial of NanoFlu™ in Older Adults
AQ
08/28NOVAVAX : to Participate at Two Upcoming Investor Conferences
AQ
08/09NOVAVAX INC : Results of Operations and Financial Condition, Financial Statement..
AQ
08/09NOVAVAX : 2Q Earnings Snapshot
AQ
08/08NOVAVAX : Management's Discussion and Analysis of Financial Condition and Result..
AQ
08/08NOVAVAX : Reports Second Quarter 2018 Financial Results
AQ
08/01NOVAVAX : to Host Conference Call to Discuss Second Quarter Financial Results on..
AQ
More news
Sector news : Biotechnology & Medical Research - NEC
10/16Sanofi's Dupixent Shows Positive Headline Results in Two Phase 3 Studies
DJ
10/11GILEAD SCIENCES : Allogene's Upsized IPO Prices at High End of Range
DJ
10/05ABBVIE : Receives Health Canada Approval of Orilissa for Endometriosis Pain Trea..
DJ
10/04J&J, Arrowhead in gene-silencing drug deal worth up to $3.7 billion
RE
10/02GILEAD SCIENCES : Allogene Sets IPO at 16 Million Shares; Sees Pricing $16-$18
DJ
More sector news : Biotechnology & Medical Research - NEC
Latest Tweets
10/17$NSPX UNKNOWN BATTERED was 55 cents 9\17. Won't be unknown 4 long? $SHMN $LV.. 
10/11Q3 2018 EPS Estimates for Novavax, Inc. $NVAX Lowered by Analyst  
10/10B. Riley Lowers Novavax Q3 2018 Earnings Estimates to ($0.12) EPS (Previously..
1
10/09$ALT $AZN $EBS $GSK $INO $JNJ $NVS $PFNX $SNY $NVAX
1
10/09Novavax upgraded to overweight from underweight at J.P. Morgan  
More tweets
Qtime:45
News from SeekingAlpha
10/09Altimmune Declines Too Much 
10/03Novavax, Inc. (NVAX) Cantor Global Healthcare Brokers Conference (Transcript) 
10/03Midday Gainers / Losers (10/03/2018) 
10/02Novavax, Inc. (NVAX) Presents at Ladenburg Thalmann 2018 Healthcare Conferenc.. 
09/25Novavax up 3% premarket on launch of mid-stage study of NanoFlu in older adul.. 
Chart NOVAVAX, INC.
Duration : Period :
Novavax, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends NOVAVAX, INC.
Short TermMid-TermLong Term
TrendsBullishBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 7
Average target price 3,67 $
Spread / Average Target 81%
EPS Revisions
Managers
NameTitle
Stanley C. Erck President, Chief Executive Officer & Director
James F. Young Chairman
Timothy Jon Hahn Senior VP-Global Manufacturing Operations
John J. Trizzino CFO, Treasurer, Chief Business Officer & Senior VP
Louis F. Fries Chief Medical Officer & Senior Vice President
Sector and Competitors
1st jan.Capitalization (M$)
NOVAVAX, INC.57.26%754
CELLTRION, INC.--.--%29 133
IQVIA HOLDINGS INC26.93%25 281
LONZA GROUP18.00%23 235
INCYTE CORPORATION-34.51%13 299
SEATTLE GENETICS, INC.36.58%11 555